Could combining biomarkers provide more accurate early diagnosis of dementia?
Published 14 July 2009
The development of essential dementia diagnostic tools could be achieved through the combined observation of biomarkers with other measures such as brain volume, according to research studies.
Previous research has typically concentrated on one area.
The study led by Dr Susan Landau involved measurement of brain volume by scans, combined with detection of the tau protein in cerebrospinal fluid (CSF) and genetic profiling. The research suggests that combining these biomarkers provided more accurate predictions of who would develop mild cognitive impairment or Alzheimer's disease.
Dr Michael Ewers and Dr Bokde combined their expertise in biomarkers and MRI imaging to tackle the complexity of dementia. They suggest combining cognitive tests with the detection of biomarkers through CSF sampling and MRI scans significantly increases accuracy of diagnosis.
Research presented by Dawn Matthews observed the amount of glucose and glucose metabolism in 32 regions of the brain using PET scans. This technology has been used to diagnose and differentiate between types of dementia. The research shows that scanning of the hippocampus was particularly accurate for diagnosing dementia.
Professor Clive Ballard
Director of Research
Alzheimer's Society
Ends
Reference:
Notes to editors
The study led by Dr Susan Landau involved measurement of brain volume by scans, combined with detection of the tau protein in cerebrospinal fluid (CSF) and genetic profiling. The research suggests that combining these biomarkers provided more accurate predictions of who would develop mild cognitive impairment or Alzheimer's disease.
Dr Michael Ewers and Dr Bokde combined their expertise in biomarkers and MRI imaging to tackle the complexity of dementia. They suggest combining cognitive tests with the detection of biomarkers through CSF sampling and MRI scans significantly increases accuracy of diagnosis.
Research presented by Dawn Matthews observed the amount of glucose and glucose metabolism in 32 regions of the brain using PET scans. This technology has been used to diagnose and differentiate between types of dementia. The research shows that scanning of the hippocampus was particularly accurate for diagnosing dementia.
'Earlier and more accurate diagnosis is a priority for improving quality of life for people with dementia. Research into biomarkers is crucial to identify how new diagnostic tools could be developed. These studies highlight the benefits of observing a variety of different factors to detect changes in the brain and reflect the complexity of dementia.
There is currently a serious lack of PET scanning facilities in the UK. As more diagnostic scanning techniques are developed, it will be essential to invest in this resource to make it more widely available to the public. More research is needed in this area to allow techniques to be perfected.
One million people will develop dementia in the next ten years, yet the government invests just 2% of its medical research budget on dementia. Dementia is the health challenge of our generation, it is absolutely vital that dementia research funding is tripled.'
Professor Clive Ballard
Director of Research
Alzheimer's Society
Ends
Reference:
- Dawn Matthews - Hippocampul glucose metabolism predicts cognitive decline
- Susan Landau - Comparing predictors of conversion Data from Alzheimer's disease Neuroimaging Initiative
- Michael Ewers - Multidimensional biomarkers based-diagnosis of early Alzheimer's disease
Notes to editors
- Alzheimer's Society researchers at ICAD are available for comment and interview on request
- The International Conference on Alzheimer's Disease is held in Vienna from 11 - 16 July. Please visit ICAD for further information.
- One in three people over 65 will die with dementia
- Alzheimer's Society research shows that 700,000 people in the UK have a form of dementia, more than half have Alzheimer's disease. In less than 20 years nearly a million people will be living with dementia. This will soar to 1.7 million people by 2051.
- Alzheimer's Society champions the rights of people living with dementia and the millions of people who care for them.
- Alzheimer's Society works in England, Wales and Northern Ireland
- Alzheimer's Society needs to raise money to help people live well with
dementia today and for research to find a cure for tomorrow. You can
donate now by calling 0845 306 0898 or visiting alzheimers.org.uk
- Alzheimer's Society provides a National Dementia Helpline, the number is 0845 300 0336 or visit alzheimers.org.uk
